Highlights
- As of 30 November 2024, Uganda has reported 745 confirmed mpox cases across 52 districts1, including 197 cases among children under 18 years. Women and girls account for 44 per cent of the cases. There have been two deaths, with an average weekly case rate of 43. The most affected is the 19–29-year age group, with more cases among males.
- Of the reported cases, 102 cases are currently receiving treatment, 546 individuals have recovered, and 95 are yet to be transferred to care facilities.
- A total of 62 cases have been reported among school-going children, with the highest numbers in the districts of Kampala (18), followed by Wakiso (15), and Mukono (10).
- UNICEF and partners have expanded their Risk Communication and Community Engagement (RCCE) pillar campaign, reaching 6.4 million people, including 3.27 million women and girls. The efforts focus on high-risk groups such as mobile groups2; people living in crowded or low hygiene environments (prisoners, students and factory workers) and individuals with multiple sexual partners.
- Through social listening activities, UNICEF gathered feedback from 14,688 individuals, with 1,634 inquiries received through the Ministry of Health (MoH) call center, mainly regarding suspected mpox cases and adolescent health concerns.
- UNICEF provided Personal Protective Equipment (PPE) to seven districts.
- The Uganda National Immunization Technical Advisory Group (UNITAG) endorsed two vaccines, MVA-BN and LC16, for high-risk groups.
- The National Drug Authority (NDA) approved the emergency use of the MVA-BN smallpox and mpox vaccine for individuals aged 12 years and older. The authorization is valid for one year.